Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response. Each participant will be treated with 8 weeks of a luteinizing hormone-releasing hormone agonist (LHRHa) plus apalutamide (APA) while genome sequence characterization is being done. Participants with biopsy specimens deemed unevaluable for genomic testing will remain on LHRHa plus APA for an additional 16 weeks. Participants with evaluable tissue will be assigned to one of the open-label sub-studies on the basis of genomic profiling results. Within each group, they will be randomized to a specific treatment arm either LHRHa plus APA alone or adding abiraterone acetate and prednisone, docetaxel or niraparib. The study will evaluate the response rate and outcomes after radical prostatectomy in each arm of the trial.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyźni w wieku 18 lat i starsi.
- •Potwierdzony rak prostaty (gruczołak), bez cech raka drobnokomórkowego.
- •Rak prostaty zlokalizowany, ale o wysokim ryzyku nawrotu (szczegółowe kryteria dotyczące wyników badań)
- •Pacjent zgadza się na pobranie krwi i analizę tkanki guza pod kątem genetycznym.
- •Brak wcześniejszego leczenia systemowego lub miejscowego raka prostaty (możliwe wyjątki, np. krótkie leczenie hormonalne przed badaniem).
- •Ogólny stan zdrowia pozwalający na udział w badaniu (dokładnie opisany w protokole badania).
✗ Disqualifies
- •Pacjenci, u których tkanka guza jest niemożliwa do analizy genetycznej (zostaną objęci innym etapem leczenia w ramach badania).
- •Pacjenci z przerzutami raka prostaty.
- •Pacjenci, u których nie ma wystarczających wyników badań laboratoryjnych.
- •Pacjenci nie wyrażający zgody na udział w badaniu.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 14, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (9)
University of California Davis
Sacramento, United States
Dana-Farber Cancer Institute / Beth Israel Deaconess Medical Center
Boston, United States
University of Michigan Health
Ann Arbor, United States
U.T. MD Anderson Cancer Center
Houston, United States
Fred Hutchinson Cancer Center
Seattle, United States
Vancouver Prostate Centre
Vancouver, Canada
London Health Sciences Centre
London, Canada
Ottawa Hospital Research Institute (OHRI)
Ottawa, Canada
University Health Network
Toronto, Canada
Trial contact
Martin E Gleave, MD
Doron Berlin
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.